1
Growth Score
pts
Heat Score
-30 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
5073878
BARD1 is a Swiss start-up developing a simple blood test for screening and diagnosing lung cancer.
- Irmgard Irminger-Finger: Co-Founder
About the Company
BARD1 is a protein released in an aberrant form by cancer cells and that is used for the diagnostic of lung cancer. BARD1AG is developing a non-invasive test based on BARD1 antibodies and RNA splice-variants. The tests are composed of an ELISA-based test (“screening”) to detect anti-BARD1 antibodies in serum, followed by an analysis of BARD1
isoforms-specific RNA in circulating tumour cells (CTCs) (“final diagnosis”). Both tests are expected to be “CE-marked” by fall 2013. The tests will be asked for by your doctor, who will first puncture a small drop of blood and send it to BARD1AG for analysis. If positive, you will be asked for a second, and somewhat larger blood sampling for definitive diagnosis.
